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GUIDELINES
Prevention and management of neutropenic sepsis in
patients with cancer: summary of NICE guidance
Robert Phillips consultant paediatric oncologist 1, Barry Hancock emeritus professor of oncology 2,
John Graham director3 consultant in clinical oncology4, Nathan Bromham senior researcher3, Huajie
Jin health economist 3, Sabine Berendse information specialist 3
1Leeds General Infirmary, Leeds LS1 3EX, UK; 2University of Sheffield, Weston Park Hospital, Sheffield S10 2SJ, UK; 3National Collaborating Centre
for Cancer, Cardiff CF10 3AF, UK; 4Taunton and Somerset NHS Foundation Trust, Taunton TA1 5DA, UK
This is one of a series of BMJ summaries of new guidelines based on
the best available evidence; they highlight important recommendations
for clinical practice, especially where uncertainty or controversy exists.
Neutropenic sepsis is a potentially fatal complication of
treatment for cancer, with mortality rates of 2-21%.1 An
investigation by the National Confidential Enquiry into Patient
Outcome and Death and a follow-up report by the National
Chemotherapy Advisory Group highlighted problems in the
management of neutropenic sepsis in adults receiving
chemotherapy.2 3The problems included inadequatemanagement
of neutropenic sepsis leading to avoidable deaths, and the lack
of systems for urgent assessment and of policies at organisation
level for dealing with neutropenic sepsis. This article
summarises themost recent recommendations from the National
Institute for Health and Clinical Excellence (NICE) on the
prevention and management of neutropenic sepsis in patients
of any age with cancer.4
Recommendations
NICE recommendations are based on systematic reviews of the
best available evidence and explicit consideration of cost
effectiveness. When minimal evidence is available,
recommendations are based on the Guideline Development
Group’s experience and opinion of what constitutes good
practice. Evidence levels for the recommendations are given in
italic in square brackets.
Information and support for patients and
carers
• Provide patients having anticancer treatment and their
carers with written and verbal information, before starting
and throughout their cancer treatment, on:
-Neutropenic sepsis
-How and when to access 24 hour specialist oncology
advice
-How and when to seek emergency care.
[Based on the experience and opinion of the Guideline
Development Group (GDG)]
Training for healthcare professionals
• Provide training on the identification and management of
neutropenic sepsis to all healthcare professionals likely to
be involved in the management of patients having cancer
treatment. [Based on the experience and opinion of the
GDG]
Reducing the risk of septic complications of
anticancer treatment
• For adult patients (aged ≥18 years) with acute leukaemias,
stem cell transplants, or solid tumours in whom clinically
significant neutropenia (neutrophil count ≤0.5 x 109/L) is
an expected consequence of chemotherapy, offer
prophylaxis with a fluoroquinolone only during the
expected period of neutropenia. The lack of data for
children and young people and for patients with
lymphomas, makes it impossible currently to recommend
the use or avoidance of a fluoroquinolone during periods
of neutropenia. [Based on moderate to high quality
evidence from systematic reviews and meta-analyses of
randomised controlled trials]
• Centres where patients are receiving fluoroquinolones for
antibiotic prophylaxis of neutropenic sepsis should monitor
rates of antibiotic resistance. [Based on the experience and
opinion of the GDG]
Correspondence to: J Graham john.graham@nhs.net
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e5368 doi: 10.1136/bmj.e5368 (Published 19 September 2012) Page 1 of 3
Practice
PRACTICE
• Do not routinely offer granulocyte colony stimulating factor
to prevent neutropenic sepsis in adults having
chemotherapy unless they are receiving this as an integral
part of the chemotherapy regimen or to maintain dose
intensity. [Based on high quality evidence from systematic
reviews and meta-analyses of randomised controlled trials
and de novo economic analysis]
Outside these indications, the role of granulocyte colony
stimulating factor in the treatment of patients with cancer is
highly controversial. An economic analysis undertaken
specifically for the guideline showed that the use of granulocyte
colony stimulating factor when given solely to prevent
neutropenic sepsis was highly unlikely to be cost effective.
Referral guidance
• Suspect neutropenic sepsis if patients having cancer
treatment become unexpectedly or seriously unwell.
• Refer patients with suspected neutropenic sepsis
immediately for assessment at their appropriate local
hospital.
[Both points are based on the experience and opinion of the
GDG]
Emergency treatment and assessment
Suspected neutropenic sepsis is an acute medical emergency.
• Start immediate empirical antibiotic treatment. [Based on
the experience and opinion of the GDG] The current
National Cancer Action Team’s guidance and measures
for cancer services suggest that treatment should be started
within one hour.5
• Use monotherapy (the combination piperacillin with
tazobactam) as initial empirical antibiotic treatment, and
do not prescribe additional aminoglycoside(s), unless there
are patient specific or local microbiological indications,
such as a high rate of resistance to piperacillin with
tazobactam. [Based on high quality evidence from
systematic reviews and meta-analyses of randomised
controlled trials]
• Do a full clinical assessment of patients, including:
– -History and examination
– -Full blood count, and kidney and liver function tests
(including albumin)
– -C reactive protein, lactate and blood culture
– -Additional peripheral blood culture, if possible, in
patients with a central venous access device to improve
the detection rates for bacteraemia
– -Urinalysis in all children aged ≤5 years.
[Based on low quality evidence from observational studies and
the experience and opinion of the GDG]
• Do not do chest radiography unless clinically indicated.
[Based on low to moderate quality evidence from
observational studies]
• Do not prescribe empiric glycopeptide antibiotics to
patients with neutropenic sepsis and a central venous access
device. [Based on very low or low quality evidence from
systematic reviews of randomised controlled trials]
• Do not remove the central venous access device as
empirical management. However, it may require removal
if it is suspected to be the focus of uncontrolled infection.
[Based on very low or low quality evidence from
observational studies]
Confirming the diagnosis
• Diagnose neutropenic sepsis in every patient whose
temperature is >38oC and neutrophil count <0.5 × 109/L.
[Based on low quality evidence from observational studies]
Assessing the patient’s risk of septic
complications
• An oncology specialist should assess every patient’s risk
of septic complications within 24 hours, using a validated
risk scoring tool. [Based on moderate quality evidence
from systematic reviews of observational studies]
No clear evidence describes the superiority of one system over
another. The box describes two commonly used systems: the
Multinational Association for Supportive Care in Cancer
(MASCC) score (for adults) and a modified Alexander rule (for
children and young people).6 7
Patients at low risk of septic complications
• Consider treating patients at low risk of developing septic
complications with outpatient antibiotic treatment, if
clinically appropriate and their domestic circumstances
will allow them to return to hospital promptly if a problem
develops. [Based on moderate quality evidence from
systematic reviews]
Patients at high risk of septic complications
• Review and repeat the risk assessment daily while the
patient is an inpatient, using the validated risk scoring tool.
[Based on the experience and opinion of the GDG]
• Switch from intravenous to oral antibiotic treatment after
48 hours in patients who are reassessed as being at low risk
of septic complications, and discharge them home if
clinically appropriate and domestic circumstances allow.
[Based on low to moderate quality evidence from
randomised trials]
• Discontinue empirical antibiotic treatment in patients who
have clinically responded to treatment—for example, by
defervesence and an absence of signs of infection,
irrespective of neutrophil count. [Based on low quality
evidence from observational studies]
• Continue inpatient empirical antibiotic treatment in patients
who have unresponsive fever unless an alternative cause
of fever is likely. [Based on the experience and opinion of
the GDG]
• Do not change primary empirical antibiotics in patients
with unresponsive fever unless there is clinical deterioration
or a specific microbiological indication. [Based on low
quality evidence from randomised trials]
Overcoming barriers
Teenagers and young adults with cancer seem to be twice as
likely to die of neutropenic sepsis as other age groups,4 and the
Guideline Development Group urges those who care for these
patients to emphasise to them the life threatening nature of this
condition. The recommendation not to use granulocyte colony
stimulating factor to prevent episodes of neutropenia challenges
conventional practice; however, granulocyte colony stimulating
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Commonly used, validated risk assessment tools for neutropenic sepsis
Multinational Association for Supportive Care in Cancer (MASSC) score for adults6
Calculate the score for each patient at admission, according to the factors and scores listed below. If the total score is 21 or higher, they
are at low risk of severe septic complications.
• Solid tumour or lymphoma with no previous fungal infection = 4
• Outpatient status (at onset of fever) = 3
• Age <60 years = 2
• Burden of illness:
-No or mild symptoms = 5
-Moderate symptoms = 3
-Severe symptoms = 0
• No hypotension (systolic BP >90 mmHg) = 5
• No chronic obstructive pulmonary disease = 4
• No dehydration = 3
Modified Alexander rule for children and young people <18 years old7
Patients are at low risk of septic complications if:
• They are not having treatment for acute myeloblastic leukaemia or Burkitt lymphoma, or the induction phase of treatment for acute
lymphoblastic leukaemia; do not have a progressive disease; or are not having treatment for relapsed disease with marrow involvement;
or
• They do not present with any of the following features: hypotension, tachypnoea or hypoxia <94%, new changes in chest radiography
results, altered mental status, severe mucositis, vomiting or abdominal pain, focal infection, other clinical reason(s) for inpatient
treatment, neutrophil count <0.1 × 109/L.
factor may be an integral part of the chemotherapy regimen or
used to maintain dose intensity in some patients having
chemotherapy with proved survival advantage. Clinicians may
need to explain clearly their decisions to use granulocyte colony
stimulating factor to healthcare commissioners. Effective
monitoring and hospital-wide asepsis should mitigate potential
problems such as antibiotic resistance patterns and Clostridium
difficile from the increased use of prophylactic fluoroquinolone
antibiotics; the GDG concluded from the available evidence
that the potential disadvantage from this was outweighed by the
reduction in mortality from neutropenic sepsis. Delivering care
outside hospital to patients at low risk of septic complications
will need careful implementation of early, risk stratified
discharge together with informed community support to enable
this to happen safely and improve the experience of patients.
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Further information on the guidance
There are many local, regional, national, and international guidelines on the management of neutropenic sepsis, and great variation in
practice in the United Kingdom.4 Few of these guidelines focus on the management of neutropenic sepsis in the NHS setting, and none has
explicitly examined the cost effectiveness of their recommendations. This NICE guideline was developed to reduce unwarranted variation
in service provision and bring into practice the most cost effective approaches to prevention and management of neutropenic sepsis. The
recommendations were developed after discussion of the relevance of the evidence to children, young people, and adults and are intended
for use in patients of any age with cancer. Where the guideline gives age limited or disease specific recommendations these are clearly
indicated as such.
Methods
This guidance was developed by the National Collaborating Centre for Cancer using methods from NICE’s standard processes (www.nice.
org.uk/guidelinesmanual). The guidance review involved literature searches to identify relevant evidence, with critical appraisal of the quality
of the identified evidence. A multidisciplinary team (the Guideline Development Group (GDG)) of service users, carers, and healthcare
professionals was established to review the evidence and develop the subsequent recommendations. The healthcare professionals in this
team included medical and clinical oncologists, haematologists, a microbiologist, an emergency medicine physician, paediatricians, an adult
acute medicine physician, and chemotherapy, paediatric, community, and haematology specialist nurses. The guidance then went through
an external consultation with stakeholders. The GDG considered the stakeholders’ comments, reanalysed the data where necessary, and
modified the guidance as appropriate.
NICE has produced three different versions of the guidance: a full version; a summary version known as the “NICE guidance”; and a version
for people using NHS services, their families and carers, and the public. All these versions are available from the NICE website. Updates
of the guidance will be produced as part of NICE’s guideline development programme.
Cost effectiveness analysis of the use of colony stimulating factors (particularly granulocyte colony stimulating factor) and
antibiotics as prophylaxis in patients at risk of neutropenic sepsis
As neutropenic sepsis affects many patients and the use of colony stimulating factors and antibiotics carries potentially substantial differences
in cost, the GDG had serious concerns about cost effectiveness. It conducted a systematic review of previous economic models, but all
studies were deemed to be at most only partially applicable to the guideline and to have very serious or potentially serious limitations.
Accordingly, the group constructed a de novo model, which examined the cost effectiveness of the use of fluoroquinolone antibiotics, colony
stimulating factors, both, or neither, in the prevention of neutropenic sepsis for adults (age >18 years) with cancer who were being treated
as outpatients and whose chemotherapy regimen did not include granulocyte colony stimulating factor (G-CSF).
Findings of the base-case economic analysis
At the NICE “willingness to pay” threshold of £20 000 (€25 000; $31 000) per quality adjusted life year:
• For patients with a solid tumour who can take fluoroquinolone, primary prophylaxis with fluoroquinolone is the most cost effective
prophylactic strategy
• For patients with a solid tumour who cannot take fluoroquinolone, no prophylaxis is the most cost effective strategy
• For patients with non-Hodgkin lymphoma or Hodgkin lymphoma, no prophylaxis is the most cost effective strategy.
All the results in the analysis were robust to both structural sensitivity analysis and probabilistic sensitivity analysis.
To test the health economic model the following scenarios were explored: 100% risk of neutropenic sepsis; 90% drug discount; five days of
G-CSF per cycle; reduced daily dose of G-CSF. The one way sensitivity analysis showed that the model was robust to all scenarios, except
if the effectiveness of fluoroquinolones versus nothing or placebo was reduced to a relative risk of ≥0.79 and if the cost of pegylated G-CSF
was discounted to £179.50 or less per dose when pegylated G-CSF became cost effective.
Future research
The guideline recommends research to:
• Assess the benefits and disadvantages of different types of support, and information about neutropenic sepsis, for patients and their
relatives
• Determine the value of symptoms and signs in patients in the community predicting neutropenic sepsis and its outcome
• Evaluate the effectiveness of very early (within 24 hours) discharge from hospital with oral antibiotics for patients with neutropenic
sepsis
• Investigate the cost effectiveness of prophylaxis of neutropenic sepsis with antibiotics and/or granulocyte colony stimulating factor
preparations in children and young people, and in adults with lymphoma, receiving cancer treatment
• Determine the incidence of suspected and proved neutropenic sepsis in a prospective national cohort study
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